Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
Repurposing Drugs in Oncology - Nitroglycerin as an anti-cancer agent

Repurposing Drugs in Oncology - Nitroglycerin as an anti-cancer agent

en English

Proceed to module  Shortlist  Rate Module  Share
Language

en English

Summary This module aims to enhance your understanding of issues around drug repurposing in global oncology medicine
Description

This module aims to enhance your understanding of issues around drug repurposing in global oncology medicine. It is based on an article published in ecancer and was developed in partnership between ecancer and ReDO.

Published May 2017.

 

Target Audience

This module has been developed to support the knowledge of practising clinicians interested in repurposing drugs in oncology. 

Learning Objectives

By the end of this module you should be able to:

  • Identify that repurposing is efficient and cost-effective, assuming we can prove efficacy
  • Be familiar with the many cancer related mechanisms of action that nitroglycerin has
  • Understand that reducing hypoxia with nitroglycerin can increase the therapeutic effect of existing chemo and chemoradiation protocols
  • Understand that additional clinical trials of nitroglycerin are warranted
Accreditation

This module no longer issues CME credits.

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Disclosure Policy

ecancer and Dr Pan Pantziarka, PhD, Anticancer Fund, Strombeek-Bever, Belgium have no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this Re-DO e-learning module. We have no disclosures to report in relation to this project.

Proceed to Module
Proceed to module  Shortlist  Rate Module


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation